Revised Fibromyalgia Impact Questionnaire

Abstract

The Revised Fibromyalgia Impact Questionnaire (FIQR) is a widely accepted, disease-specific patient-reported outcome measure (PROM) developed to capture the total spectrum of functional impairment, symptom burden, and overall health-related quality of life (HRQoL) in patients diagnosed with fibromyalgia syndrome (FMS). Introduced by Robert M. Bennett and colleagues in 2009, the FIQR was engineered to overcome the psychometric, administrative, and clinical limitations of the original 1991 Fibromyalgia Impact Questionnaire (FIQ) developed by Carol S. Burckhardt, Sharon R. Clark, and Robert M. Bennett. Comprising 21 items across three discrete, empirically substantiated domains—Physical Function (9 items), Overall Impact (2 items), and Symptoms (10 items)—the instrument assesses patient status over the recall window of the past seven days.

Every item is scored on an 11-point numeric rating scale (NRS) anchored from 0 to 10 with domain-tailored qualitative descriptors. The scoring algorithm applies differential algebraic weighting factors to equate the subscales to standardized maxima: Physical Function contributes up to 30 points (raw sum divided by 3), Overall Impact accounts for up to 20 points (raw sum unweighted), and Symptoms contributes up to 50 points (raw sum divided by 2). This yields a total composite score ranging from 0 to 100, where higher scores directly reflect more severe functional deterioration and disease impact. The FIQR exhibits exceptional psychometric stability across diverse clinical and cross-cultural cohorts, consistently demonstrating internal consistency with Cronbach’s alpha coefficients exceeding 0.90 for the total score and ranging from 0.80 to 0.93 across subdomains. Test-retest reliability across intervals spanning one to two weeks routinely yields intraclass correlation coefficients (ICC) between 0.82 and 0.95. Construct, convergent, and divergent validities have been corroborated against legacy measures, including the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), the Health Assessment Questionnaire (HAQ), and the Beck Depression Inventory (BDI), making it a global gold standard in clinical trials and routine rheumatologic practice.

Keywords

Fibromyalgia, Revised Fibromyalgia Impact Questionnaire, FIQR, chronic widespread pain, central sensitization, patient-reported outcome measure, psychometrics, physical function, rheumatology, functional disability, health status assessment, symptom burden, pain measurement, quality of life, outcome assessment.

Authors

The conceptualization, design, and empirical validation of the original Fibromyalgia Impact Questionnaire (FIQ) and its subsequent revision (FIQR) were conducted by distinguished clinician-scientists in rheumatology, nursing, psychology, and health services research:

• Robert M. Bennett, M.D., F.R.C.P., M.A.C.R.: Professor Emeritus of Medicine and Division Head of Arthritis and Rheumatic Diseases at the Oregon Health & Science University (OHSU), Portland, Oregon, United States. Dr. Bennett is an internationally renowned pioneer in fibromyalgia pathogenesis, neuroendocrine dysregulation, and outcome metrics.
• Carol S. Burckhardt, Ph.D., R.N.: Late Professor at the School of Nursing, Oregon Health & Science University. Dr. Burckhardt was a preeminent scholar in chronic pain coping, quality-of-life assessment, and patient education.
• Sharon R. Clark, Ph.D., R.N., F.N.P.: Professor Emerita at the School of Nursing, Oregon Health & Science University, whose research specialized in multidisciplinary lifestyle interventions, aerobic conditioning, and non-pharmacologic therapies for fibrositis and chronic widespread pain.
• Ronald Friend, Ph.D.: Professor Emeritus of Psychology at Stony Brook University (State University of New York at Stony Brook), an expert in psychometrics, structural equation modeling, and health psychology who co-led the redesign and factor structure validation of the FIQR.
• Kim D. Jones, Ph.D., R.N., F.N.P., F.A.A.N.: Professor and Dean, School of Nursing, Linfield University, and former Associate Professor of Medicine and Nursing at OHSU, specializing in exercise physiology and fibromyalgia symptom clusters.
• Rachel Ward, B.S., Bruce K. Han, M.D., and Rebecca L. Ross, M.S.: Key investigators and clinical trial coordinators at the Fibromyalgia Research Team, Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University.
• Dutch Adaptation Authors: The official Dutch linguistic and cultural validation was completed by Thea R. Zijlstra, Erik Taal, Mart A. F. J. van de Laar, and Johannes J. Rasker at the Department of Rheumatology, Medisch Spectrum Twente and the University of Twente, Enschede, The Netherlands (2007).

Purpose

Fibromyalgia is a debilitating, heterogeneous syndrome characterized by widespread neurogenic musculoskeletal pain, fatigue, unrefreshing sleep, cognitive disruptions (“fibro fog”), somatic hypervigilance, and mood disturbances. Because fibromyalgia lacks definitive laboratory biomarkers or pathognomonic imaging findings, clinical management and experimental research rely on standardized psychometric measures. The original 1991 FIQ was created to consolidate the fragmented measurement tools of the late 20th century into a single disease-specific questionnaire evaluating clinical status, disease progression, and therapeutic efficacy over time.

Despite its widespread adoption, the 1991 FIQ possessed operational and psychometric shortcomings that became increasingly evident over two decades of clinical trials. The original instrument utilized a heterogeneous mixture of measurement scales, including visual analog scales (VAS) measured in centimeters, multiple-choice categorical items, and continuous time metrics (such as days felt good or days missed work). Calculating scores required a mathematically complex, error-prone manual transformation of raw responses to a normalized 0–10 metric. Furthermore, several items in the physical functioning subscale contained historical socio-normative and gender biases—such as performing yard work, vacuuming a rug, cooking meals, or doing laundry—which led to high rates of missing data or non-applicability among male patients and urban demographics. Additionally, modern neurobiological discoveries revealed that key hallmark features of fibromyalgia, such as cognitive dysfunction (memory and concentration deficits), balance and spatial instability, and generalized environmental hypersensitivity (hyperacusis, photophobia, osmophobia, and thermal allodynia), were completely omitted from the original FIQ.

To resolve these deficiencies, Bennett and colleagues formulated the Revised Fibromyalgia Impact Questionnaire (FIQR) in 2009. The primary purposes of the FIQR are:

• To provide an administratively clean, rapid, patient-friendly evaluation that can be reliably completed in under three minutes without administrative supervision.
• To eliminate gender-biased and culturally restrictive activities of daily living (ADLs), ensuring broad demographic applicability across socioeconomic, gender, and age cohorts.
• To standardize the entire instrument on a unified, intuitive 11-point numeric rating scale (0 to 10), which eliminates measuring errors common to 10-centimeter visual analog scales in digital, computer-assisted, or mobile health (mHealth) implementations.
• To broaden the clinical domain capture by incorporating neurosensory, cognitive, and somatic symptoms identified by the American College of Rheumatology (ACR) and the Outcome Measures in Rheumatology (OMERACT) fibromyalgia working group.
• To maintain backward comparability and conceptual equivalence with the original FIQ while achieving psychometric properties suitable for longitudinal monitoring, phase III randomized controlled trials (RCTs), and real-world clinical documentation.

Psychological Construct

The FIQR measures the overarching multidimensional construct of Fibromyalgia Disease Burden, conceptualized as the systemic disruption imposed by central pain amplification upon somatic capability, daily life, and psychological equilibrium. This construct operates through three interconnected, empirically derived domains: Physical Function, Overall Impact, and Symptoms.

1. Physical Function (Items 1–9)

The Physical Function dimension captures perceived functional capacity across a graded spectrum of biomechanical, musculoskeletal, and endurance-dependent tasks. Rather than focusing on obsolete domestic roles, the FIQR measures functional actions of the upper extremities, lower extremities, and core axial stability:

• Proximal upper limb mobility and fine motor coordination: Item 1 evaluates the ability to brush or comb hair, requiring sustained shoulder abduction, external rotation, and cervical muscle recruitment.
• Cardiorespiratory endurance and lower-extremity ambulation: Item 2 tests continuous walking for 20 minutes, tapping into aerobic capacity, peripheral vascular flow, and musculoskeletal endurance. Item 6 assesses stair climbing (ascending a single flight), which demands concentric quadriceps activation, joint stability, and dynamic balance under gravity.
• Instrumental activities of daily living (IADLs): Items 3, 4, 5, 7, and 9 assess home meal preparation, floor cleaning (sweeping, vacuuming, mopping), lifting and carrying loaded grocery bags, changing bed linens, and grocery shopping. These activities measure composite motor functions involving repeated bending, spinal loading, bilateral grip strength, and sustained physical exertion.
• Static postural tolerance: Item 8 assesses the patient’s capacity to sit continuously in an office or kitchen chair for 45 minutes, probing postural muscle exhaustion, ischemic soft-tissue pressure pain, and axial stiffness.

2. Overall Impact (Items 10–11)

The Overall Impact subscale reflects the cognitive and emotional appraisal of functional limitation, representing the psychological burden of living with a chronic, intractable condition:

• Goal attainment interference: Item 10 asks whether fibromyalgia prevented the patient from accomplishing personal, occupational, domestic, or social goals throughout the preceding seven days. This probes the patient’s perceived disruption of agency and instrumental productivity.
• Symptom overwhelm and loss of self-efficacy: Item 11 evaluates the frequency or intensity with which the respondent felt completely overwhelmed by their fibromyalgia symptoms. This item measures emotional resilience, psychological exhaustion, demoralization, and the erosion of perceived behavioral control under chronic neurosensory stress.

3. Symptoms (Items 12–21)

The Symptoms dimension evaluates the severity of the polymorphic neurosensory, somatic, and affective manifestations that characterize central pain processing syndromes:

• Core sensory pain and hyperalgesia: Item 12 assesses spontaneous, widespread background pain. Item 19 measures allodynia and hyperpathia via tenderness to light touch, assessing the clinical hallmark of central sensitization.
• Energy and restorative sleep architecture: Item 13 evaluates profound systemic exhaustion, fatigue, and lack of energy. Item 15 measures poor sleep quality, reflecting non-restorative alpha-wave intrusion during delta-wave slow-wave sleep.
• Musculoskeletal stiffness: Item 14 assesses morning and post-inactivity musculoskeletal stiffness, reflecting gel phenomena and neurogenic muscle hypertonicity.
• Affective co-morbidities: Item 16 quantifies depression (depressive mood, loss of interest, vegetative affective signs), while Item 18 assesses generalized anxiety, internal tension, autonomic hyperarousal, and somatic worry.
• Cognitive dysfunction (“fibro fog”): Item 17 assesses memory impairments, subjective working-memory degradation, and processing speed deficits caused by pain distraction and prefrontal cortex hypoactivation.
• Neuromuscular coordination and dynamic equilibrium: Item 20 evaluates subjective balance instability and vestibular disequilibrium, capturing cerebellar-proprioceptive disruptions common in FMS.
• Environmental multisensory allodynia: Item 21 measures generalized sensory hypersensitivity across four distinct environmental domains: loud noises (hyperacusis), bright lights (photophobia), chemical or environmental odors (hyperosmia), and ambient cold exposure (thermal allodynia).

Theoretical Framework

The psychometric architecture of the FIQR is grounded in the convergence of modern pain neuroscience, cognitive-behavioral psychology, and the biopsychosocial model of disease.

1. The Biopsychosocial Model

Pioneered by George L. Engel (1977), the biopsychosocial model posits that health outcomes cannot be understood purely through biomedical pathophysiology, but instead emerge from dynamic interactions across biological, psychological, and social systems. The FIQR operationalizes this model by integrating somatic markers (pain, stiffness, hypersensitivity) with psychological responses (depression, anxiety, subjective overwhelm) and social role functioning (goal attainment, occupational capability, ADL execution). By giving proportional weight to physical function, systemic symptoms, and overall emotional-role burden, the scale prevents clinical tunnel vision on pain intensity alone.

2. Neurobiology of Central Sensitization

The contemporary neurobiological framework of fibromyalgia is defined by Central Sensitization, as conceptualized by Clifford Woolf and colleagues. In this state, sustained nociceptive input, paired with defective descending analgesia via descending noradrenergic and serotonergic pathways (diffuse noxious inhibitory control deficits), results in dorsal horn hyperexcitability, neuroinflammation, and widespread cortical amplification. This neurosensory hypersensitivity explains why fibromyalgia extends far beyond localized somatic pain. By including items evaluating balance instability, cognitive deficits, and multisensory allodynia (sound, light, smell, cold), the FIQR aligns with current neurobiological understandings of widespread sensory amplification.

3. The International Classification of Functioning, Disability and Health (ICF)

The World Health Organization’s (WHO) ICF model organizes health along three distinct axes: Body Functions and Structures, Activities, and Participation. The FIQR maps directly to this taxonomy:

• Body Functions and Structures: Evaluated by the Symptoms domain (sensory pain, tenderness, unrefreshing sleep, muscular stiffness, depressive affect, anxiety, cognitive executive function).
• Activities: Evaluated by the Physical Function domain (carrying groceries, ascending stairs, walking, sitting, personal hygiene).
• Participation: Evaluated by the Overall Impact domain (interference with life goals, feeling overwhelmed, and restrictions in occupational or domestic engagement).

4. Cognitive-Affective Processing and the Fear-Avoidance Model

The instrument draws conceptually on the Fear-Avoidance Model of Chronic Pain (Vlaeyen & Linton, 2000). When bodily sensations are interpreted as threatening, catastrophic misinterpretations prompt hypervigilance and kinesiophobia (fear of movement). This fuels behavioral avoidance, muscular deconditioning, functional disability, and depressive withdrawal. Items assessing the feeling of being overwhelmed and functional task performance directly monitor the downstream behavioral disruptions predicted by this framework.

Validity

The validity of the FIQR has been extensively documented in international multicenter trials, cross-sectional cohort evaluations, and clinical research networks.

1. Construct and Structural Validity

Construct validity was established by Bennett et al. (2009) during initial validation in a diverse online and clinical cohort of over 1,100 patients with fibromyalgia. The instrument was benchmarked against the original FIQ. Bennett and colleagues demonstrated a high correlation between the original FIQ total score and the newly designed FIQR total score (r = 0.88, p < 0.001), indicating strong construct equivalence despite changes in scoring, layout, and content. The three subdomains of the FIQR showed moderate-to-high correlations with their corresponding original FIQ domains, confirming structural alignment while offering broader clinical coverage.

2. Convergent and Criterion Validity

Convergent validity has been established by evaluating correlations between FIQR domain scores and established generic and disease-specific outcome measures:

• SF-36 Physical and Mental Component Summaries: The FIQR Physical Function subscale correlates strongly with the SF-36 Physical Component Summary (PCS) (r = -0.73 to -0.81, p < 0.001). Conversely, the FIQR Overall Impact and affective symptom items correlate strongly with the SF-36 Mental Component Summary (MCS) (r = -0.65 to -0.74).
• Health Assessment Questionnaire (HAQ): The FIQR Physical Function domain correlates robustly with the HAQ Disability Index (r = 0.70 to 0.79), confirming that the revision successfully measures physical impairment without gender-biased activities.
• Psychological Distress Measures: The depression and anxiety items on the FIQR correlate strongly with the Beck Depression Inventory (BDI-II; r = 0.68 to 0.76) and the Hospital Anxiety and Depression Scale (HADS; r = 0.64 to 0.72).
• Pain Assessment Scales: The pain item (Item 12) demonstrates high convergent alignment with the Brief Pain Inventory (BPI) Worst Pain and Pain Severity indices (r = 0.75 to 0.84).

3. Discriminant and Known-Groups Validity

The FIQR reliably differentiates between clinical populations and healthy individuals, as well as between differing levels of disease severity. In validation trials, healthy control cohorts yielded mean FIQR total scores under 12 (± 8.4), whereas patients diagnosed with FMS under the ACR 1990 and 2010 criteria produced mean scores of 56.6 (± 19.8) to 63.4 (± 21.2). The scale also distinguishes fibromyalgia from other chronic rheumatologic and systemic autoimmune conditions, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Patients with fibromyalgia score significantly higher on the Symptoms and Overall Impact subscales than patients with non-fibromyalgia musculoskeletal conditions, even when physical function impairment scores are comparable.

4. Responsiveness to Change and Sensitivity

A vital metric for clinical trials is responsiveness to therapeutic interventions. The FIQR has been validated in multicenter clinical trials evaluating pharmacological interventions (e.g., pregabalin, duloxetine, milnacipran) and non-pharmacological modalities (e.g., cognitive behavioral therapy, aquatic exercise, graded aerobic conditioning). Responsiveness metrics consistently report large effect sizes (Cohen’s d ranging from 0.55 to 0.85). The Minimal Clinically Important Difference (MCID) of the FIQR has been estimated using both anchor-based and distribution-based methods (Salaffi et al., 2013). A reduction of 14% or 8.1 to 13.0 points on the total 100-point scale indicates a clinically meaningful, observable reduction in disease severity.

Reliability

The FIQR exhibits high reliability across diverse study populations, translations, and clinical settings. Research has consistently demonstrated strong internal consistency and temporal stability.

1. Internal Consistency

Internal consistency evaluates the interrelatedness of scale items within an underlying construct. Across international psychometric evaluations, the FIQR yields Cronbach’s alpha coefficients that exceed established measurement standards (typically alpha ≥ 0.70 for research, ≥ 0.90 for individual clinical decision-making):

• FIQR Total Score: Cronbach’s alpha values range from 0.91 to 0.95 across American, Spanish, German, Dutch, Italian, Turkish, and Japanese cohorts.
• Physical Function Subscale: Cronbach’s alpha values range from 0.85 to 0.93, indicating strong scale homogeneity across upper- and lower-extremity items without redundancy.
• Overall Impact Subscale: Cronbach’s alpha values range from 0.80 to 0.88. This is notable for a two-item domain, as Cronbach’s alpha is inherently sensitive to small item counts.
• Symptoms Subscale: Cronbach’s alpha values range from 0.84 to 0.91, confirming that the expanded symptom profile (including cognition, equilibrium, and environmental sensitivity) reflects a cohesive symptom cluster.

2. Test-Retest Reliability and Temporal Stability

Test-retest stability measures the reproducibility of test scores across stable intervals. In the initial psychometric evaluation by Bennett et al. (2009), patients were retested over a 7-day interval without intervening therapeutic changes. The intraclass correlation coefficient (ICC) for the FIQR Total Score was 0.82 to 0.91.

Subsequent international validation studies corroborated these results. For example, the Spanish validation by Luciano et al. (2013) demonstrated an ICC of 0.88 (95% CI [0.83, 0.92]), while the Italian adaptation by Salaffi et al. (2013) found ICC values of 0.93 for the total score, 0.90 for Physical Function, 0.84 for Overall Impact, and 0.89 for Symptoms. The standard error of measurement (SEM) remains low (typically between 3.2 and 4.8), confirming that the instrument has minimal measurement noise across repeated administrations.

Factor Analysis

The structural dimensionality of the FIQR has been evaluated using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA), consistently confirming its three-dimensional structure.

1. Exploratory Factor Analysis (EFA)

During development, Bennett, Friend, and colleagues performed EFA using principal axis factoring with promax and oblimin oblique rotations, allowing underlying dimensions to correlate naturally. Scree plot analyses, Kaiser’s eigenvalue-greater-than-one rule, and parallel analysis identified three primary factors that accounted for more than 60% of the total variance:

• Factor 1 (Physical Function): All 9 functional items (Items 1 to 9) loaded cleanly onto this factor, with factor loadings ranging from 0.58 to 0.87, and minimal cross-loadings (< 0.25) onto the other two factors.
• Factor 2 (Symptoms): All 10 symptom items (Items 12 to 21) loaded strongly onto this latent construct, with factor loadings ranging between 0.46 and 0.82. The pain, fatigue, stiffness, sleep, and memory items showed the highest loadings.
• Factor 3 (Overall Impact): Items 10 and 11 loaded heavily onto this factor, with primary loadings exceeding 0.78.

2. Confirmatory Factor Analysis (CFA)

Subsequent independent validation studies employed CFA to evaluate whether the theoretical three-factor model held up across international and linguistic cohorts. In the CFA models, the three-factor structure consistently outperformed one-factor and two-factor models across standard goodness-of-fit indices:

Bifactor modeling has also been conducted to evaluate whether an overarching general factor (“General Fibromyalgia Burden”) coexists with specific domain traits. These analyses show that while the general factor accounts for roughly 75% of the common variance, the three specific domain factors retain substantial reliable variance, justifying the use of both the total score and distinct subscale profiles in research and clinical contexts.

Instrument / Measurement Tool

• Full Instrument Name: Revised Fibromyalgia Impact Questionnaire (FIQR)
• Legacy Form: Fibromyalgia Impact Questionnaire (FIQ; Burckhardt, Clark, & Bennett, 1991)
• Test Type: Patient-Reported Outcome Measure (PROM); disease-specific health status questionnaire
• Administration Format: Self-administered questionnaire (Paper-and-pencil, computerized desktop, tablet, or web-based mobile format)
• Target Population: Adults (aged ≥ 18 years) and geriatric patients diagnosed with fibromyalgia syndrome (FMS) or evaluated for chronic widespread pain
• Completion Time: Under 3 minutes (typically 2 to 3 minutes)
• Recall Period: The preceding seven (7) days
• Item Count: 21 items total, organized into three distinct subdomains:
  • Physical Function: 9 items (Items 1 through 9)
  • Overall Impact: 2 items (Items 10 and 11)
  • Symptoms: 10 items (Items 12 through 21)
• Response Scale: 11-point numeric rating scale from 0 to 10 (with domain-specific anchors: 0 = No difficulty / Never / None to 10 = Very difficult / Always / Extreme)
• Reverse-Scoring: None. All items are scored positively, where higher numbers indicate greater functional impairment or symptom severity.
• Detailed Scoring Algorithm:
  • Physical Function Subscale Score: Sum the raw scores of Items 1 through 9 (range: 0 to 90) and divide the sum by 3. Maximum domain score = 30.
  • Overall Impact Subscale Score: Sum the raw scores of Items 10 and 11 (range: 0 to 20). No division applied (multiplier = 1). Maximum domain score = 20.
  • Symptoms Subscale Score: Sum the raw scores of Items 12 through 21 (range: 0 to 100) and divide the sum by 2. Maximum domain score = 50.
  • Total FIQR Score: Sum the three calculated domain scores: Total = Physical Function + Overall Impact + Symptoms. Range: 0 to 100.
• Handling of Missing Data: If two or fewer items are missing in the Physical Function domain, the mean of the completed items can be imputed for the missing values before dividing by 3. If any item is missing in the Overall Impact domain, the domain cannot be scored reliably. If two or fewer items are missing in the Symptoms domain, mean imputation may be used before dividing by 2. If more than three items across the full instrument are omitted, the total score should be treated as missing.
• Clinical Severity Cut-Off Stratifications:
  • 0 to 38: Mild fibromyalgia impact
  • 39 to 58: Moderate fibromyalgia impact
  • 59 to 100: Severe to extreme fibromyalgia impact

Permissions & Fee and Test Year

• Initial Publication Year of the Original FIQ: 1991
• Publication Year of the Revised FIQR: 2009
• Year of Validated Dutch Adaptation: 2007 (Zijlstra et al.)
• Copyright and Intellectual Property: © 2009 Robert M. Bennett, Carol S. Burckhardt, Sharon R. Clark, and Ronald Friend. All rights reserved.
• Licensing and Accessibility: The FIQR is widely available for non-commercial academic research, public health investigations, independent student scholarship, and routine clinical patient care at no financial cost. Researchers and clinicians may utilize the scale without formal prior authorization, provided that full bibliographic attribution is maintained and the items, anchors, and scoring formulas remain unaltered.
• Commercial and Industry Use: For use within for-profit clinical trials, pharmaceutical-sponsored investigations, or integration into proprietary electronic medical record (EMR) software platforms, commercial licensing agreements must be secured through the copyright holders and the Technology Transfer Office at Oregon Health & Science University (OHSU).

References

• Bennett, R. M., Bushmakin, A. G., Cappelleri, J. C., Zlateva, G., & Sadosky, A. B. (2009). Minimal clinically important difference in the Fibromyalgia Impact Questionnaire. The Journal of Rheumatology, 36(6), 1304–1311. https://doi.org/10.3899/jrheum.081090
• Bennett, R. M., Friend, R., Jones, K. D., Ward, R., Han, B. K., & Ross, R. L. (2009). The Revised Fibromyalgia Impact Questionnaire (FIQR): Validation and psychometric properties. Arthritis Research & Therapy, 11(4), R120. https://doi.org/10.1186/ar2783
• Burckhardt, C. S., Clark, S. R., & Bennett, R. M. (1991). The Fibromyalgia Impact Questionnaire: Development and validation. The Journal of Rheumatology, 18(5), 728–733. https://pubmed.ncbi.nlm.nih.gov/1865419/
• Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460
• Luciano, J. V., Aguado, J., Peñarrubia-María, M. T., Serrano-Blanco, A., Moreno-Peral, P., & García-Campayo, J. (2013). Psychometric properties of the Revised Fibromyalgia Impact Questionnaire (FIQR) in Spanish patients. Clinical and Experimental Rheumatology, 31(6 Suppl 79), S137–S145. https://pubmed.ncbi.nlm.nih.gov/24373400/
• Salaffi, F., Di Carlo, M., Carotti, M., Farah, S., & Gutierrez, M. (2013). The Italian version of the Revised Fibromyalgia Impact Questionnaire (FIQR): Cross-cultural adaptation and validation. Clinical and Experimental Rheumatology, 31(6 Suppl 79), S66–S73. https://pubmed.ncbi.nlm.nih.gov/24373390/
• Vlaeyen, J. W., & Linton, S. J. (2000). Fear-avoidance and its consequences in chronic musculoskeletal pain: A state of the art. Pain, 85(3), 317–332. https://doi.org/10.1016/S0304-3959(99)00242-0
• Wolfe, F., Clauw, D. J., Fitzcharles, M. A., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B., & Yunus, M. B. (2010). The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care & Research, 62(5), 600–610. https://doi.org/10.1002/acr.20140
• Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., Fam, A. G., Farber, S. J., Fiechtner, J. J., Franklin, C. M., Gatter, R. A., Hamaty, D., Lessard, J., Lichtbroun, A. S., Masi, A. T., … Sheon, R. P. (1990). The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis & Rheumatism, 33(2), 160–172. https://doi.org/10.1002/art.1780330203
• Woolf, C. J. (2011). Central sensitization: Implications for the diagnosis and treatment of pain. Pain, 152(3 Suppl), S2–S15. https://doi.org/10.1016/j.pain.2010.09.030
• Zijlstra, T. R., Taal, E., van de Laar, M. A., & Rasker, J. J. (2007). Validation of the Dutch translation of the Fibromyalgia Impact Questionnaire. Rheumatology (Oxford, England), 46(1), 131–134. https://doi.org/10.1093/rheumatology/kel192

Items of the Scale